Wissenschaftliche Publikationen unserer Abteilung

1. Al Taleb Z, Hierlmeier I, Heilmann H, Jung M, Bartholomä M, Bufe B.
Correction: Assessing the potential of bacterial signal peptides for radiopharmaceutical applications. 
Sci Rep. 2026 Feb 3;16(1):4726. doi: 10.1038/s41598-026-36486-2. Erratum for: Sci Rep. 2025 Sep 12;15(1):32479. doi: 10.1038/s41598-025-18831-z. PMID: 41634210; PMCID: PMC12868867.
Download PDF

2. Khreish F, Rosar F, Burgard C, Petto S, Maus S, Stemler T, Bartholomä M, Sabet A, Schaefer-Schuler A, Ezziddin S. 
Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression. 
EJNMMI Res. 2026 Feb 24;16(1):49. doi: 10.1186/s13550-026-01394-z. PMID: 41733872; PMCID: PMC13035963.
Download PDF

3. Ebert N, Rosar F, Burgard C, Bartholomä M, Maus S, Hein C, Blickle A, Ezziddin S, Khreish F. 
Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience. 
EJNMMI Res. 2026 Mar 16;16(1):59. doi: 10.1186/s13550-026-01408-w. PMID: 41838335; PMCID: PMC13066050.
Download PDF

4. Bastian MB, Kyriakou I, Rosar F, Blickle A, Burgard C, Speicher T, Ezziddin S. 
FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter? 
Q J Nucl Med Mol Imaging. 2026 Mar 30. doi: 10.23736/S1824-4785.26.03686-1. Epub ahead of print. PMID: 41910579.

5. Speicher T, Latell S, Blickle A, Bastian MB, Maus S, Schaefer-Schuler A, Bartholomä M, Misirci M, Burgard C, Ezziddin S, Rosar F. 
Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study. 
Eur J Nucl Med Mol Imaging. 2026 Apr 6. doi: 10.1007/s00259-026-07854-x. Epub ahead of print. PMID: 41940956.

6. Rosar F, Khreish F, Burgard C, Fursov A, Blickle A, Bartholomä M, Maus S, Bastian MB, Speicher T, Schaefer-Schuler A, Ezziddin S. 
Comparison of mCRPC [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting. 
Eur J Nucl Med Mol Imaging. 2026 Apr;53(5):3034-3041. doi: 10.1007/s00259-025-07682-5. Epub 2025 Nov 28. PMID: 41309998.

7. Rosar F, Burgard C, Hoang SPT, Blickle A, Bartholomä M, Maus S, Hein C, Bastian MB, Speicher T, Schaefer-Schuler A, Ezziddin S. 
Outcome and Safety of Radioligand Therapy With [161 Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [177 Lu]Lu-PSMA-617. 
Clin Nucl Med. 2026 Jun 1;51(6):e356-e361. doi: 10.1097/RLU.0000000000006384. Epub 2026 Apr 24. PMID: 42080618; PMCID: PMC13132088.
Download PDF
 

1. Rosar F, Petto S, Ganz S, Burgard C, Maus S, Bartholomä M, Miederer I, Schreckenberger M, Ezziddin S, Schaefer-Schuler A. 
Assessment of scintigraphic imaging with Terbium-161: A visual and quantitative analysis. 
Appl Radiat Isot. 2025 Dec;226:112171. doi: 10.1016/j.apradiso.2025.112171. Epub 2025 Sep 9. PMID: 40945120.
Download PDF

2. Rosar F, Blickle A, Bastian MB, Speicher T, Schaefer-Schuler A, Burgard C, Maus S, Ezziddin S. 
Auger Emitting [¹⁶¹Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal Carcinomatosis. 
Nucl Med Mol Imaging. 2026 Feb;60(1):54-56. doi: 10.1007/s13139-025-00973-7. Epub 2025 Dec 2. PMID: 41664810; PMCID: PMC12882890.

3. Al Taleb Z, Hierlmeier I, Heilmann H, Jung M, Bartholomä M, Bufe B. 
Assessing the potential of bacterial signal peptides for radiopharmaceutical applications.
Sci Rep. 2025 Sep 12;15(1):32479. doi: 10.1038/s41598-025-18831-z. Erratum in: Sci Rep. 2026 Feb 3;16(1):4726. doi: 10.1038/s41598-026-36486-2. PMID: 40940450; PMCID: PMC12432127.

4. Stögbauer J, Kämpfer N, Kindermann I, Zimmer A, Vennavaram M, Dupeyrat C, Klein C, Schappe L, Rosar F, Groppa S, Dillmann U. 
Neurological Examinations of Patients Initially Diagnosed With Wild-Type Transthyretin Amyloidosis (wtATTR).
Eur J Neurol. 2025 Sep;32(9):e70353. doi: 10.1111/ene.70353. PMID: 40999840; PMCID: PMC12464439.
Download PDF

5. Stögbauer J, Schegerer V, Berger FK, Schulz-Schaeffer W, Fassbender K, Naumann J, Smola S, Eisenbeis J, Bewarder M, Rosar F, Kettner M, Gilcher T, Diedrich S, Fousse M. 
Severe coxsackie virus B5 encephalitis mimics autoimmune limbic encephalitis in a young woman under long-term B-cell depletion with ocrelizumab: A case report. 
Mult Scler. 2025 Sep;31(10):1258-1261. doi: 10.1177/13524585251322327. Epub 2025 Feb 27. PMID: 40012477.

6. Rosar F, Burgard C, Petrescu C, Blickle A, Bartholomä M, Maus S, Bastian MB, Speicher T, Schaefer-Schuler A, Ezziddin S. 
Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry. 
Theranostics. 2025 Aug 16;15(17):9019-9028. doi: 10.7150/thno.115831. PMID: 40963912; PMCID: PMC12439265.
Download PDF

7. Speicher T, Bastian MB, Blickle A, Atzinger A, Rosar F, Burgard C, Ezziddin S. 
Advancing patient education in PRRT through large language models: challenges and potential. 
Am J Nucl Med Mol Imaging. 2025 Aug 15;15(4):146-152. doi: 10.62347/OAHP6281. PMID: 40980741; PMCID: PMC12444397.
Download PDF

8. Bastian MB, Speicher T, Blickle A, Burgard C, Bastian JLD, Bartholomä M, Schaefer-Schuler A, Maus S, Ezziddin S, Rosar F. 
Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia. 
EJNMMI Res. 2025 Jul 6;15(1):82. doi: 10.1186/s13550-025-01280-0. PMID: 40619537; PMCID: PMC12229971.
Download PDF

9. Bartholomä M, Rosar F, Burgard C, Maus S, Schreck MV, Ezziddin S. 
Novel 64Cu-labeled Trimeric PSMA Ligand Unequivocally Identifies Local Recurrence of Prostate Cancer Ambiguously Imaged by 18F-DCFPyL PSMA PET CT. 
Clin Nucl Med. 2025 Jun 4. doi: 10.1097/RLU.0000000000006010. Epub ahead of print. PMID: 40472262.

10. Wendler T, Rogasch JMM, Bastian MB, Burchert W, Hellwig D, Kaiser L, Lohmann P, Rosar F, Schemmer B, Tran-Gia J, Miederer I. 
Correction: Digitalization of Nuclear Medicine in Germany - Status Quo 2024. 
Nuklearmedizin. 2025 May 20. English. doi: 10.1055/a-2604-5823. Epub ahead of print. Erratum for: Nuklearmedizin. 2025 Apr;64(2):156-162. doi: 10.1055/a-2502-1728. PMID: 40393668.
Download PDF

11. Hierlmeier I, Randhawa P, McNeil BL, Oliveri E, Maus S, Radchenko V, Rosar F, Ezziddin S, Bartholomä MD. 
Radiochemistry of cyclen-derived chelators comprising five-membered azaheterocyclic arms with 212Pb2+,
213Bi3+, and 225Ac3. 
Nucl Med Biol. 2025 May 28;146-147:109034. doi: 10.1016/j.nucmedbio.2025.109034. Epub ahead of print. PMID: 40450922.
Download PDF

12. Bastian MB, Wörl B, Blickle A, Burgard C, Speicher T, Bartholomä M, Schaefer-Schuler A, Maus S, Ezziddin S, Rosar F. 
Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3). 
Eur J Nucl Med Mol Imaging. 2025 May 26. doi:
10.1007/s00259-025-07346-4. Epub ahead of print. PMID: 40418331.
Download PDF

13. Bastian MB, Wörl B, Blickle A, Burgard C, Speicher T, Wessendorf J, Bartholomä M, Schaefer-Schuler A, Maus S, Ezziddin S, Rosar F. 
PSMA Radioligand Therapy in Advanced Age: Insights From an 85y+ mCRPC Patient Cohort. 
Clin Nucl Med. 2025 May 12. doi: 10.1097/RLU.0000000000005968. Epub ahead of print. PMID: 40358397.

14. Wendler T, Rogasch JMM, Bastian MB, Burchert W, Hellwig D, Kaiser L, Lohmann P, Rosar F, Schemmer B, Tran-Gia J, Miederer I. 
Digitalization of Nuclear Medicine in Germany - Status Quo 2024. 
Nuklearmedizin. 2025 Apr;64(2):156-162. doi: 10.1055/a-2502-1728. Epub 2025 Apr 17. Erratum in: Nuklearmedizin. 2025 May 20. doi: 10.1055/a-2604-5823. PMID: 40245882; PMCID: PMC12020657.
Download PDF

15. Burgard C, Frei M, Blickle A, Hartrampf PE, Hoffmann MA, Schreckenberger M, Schmid HP, Unterrainer L, Rogasch J, Galler M, Ezziddin S, Rosar F. 
PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007. 
Eur J Nucl Med Mol Imaging. 2025 Apr 30. doi: 10.1007/s00259-025-07292-1. Epub ahead of print. PMID: 40304782.
Download PDF

16. Speicher T, Burgard C, Rosar F, Bastian M, Bartholomä M, Maus S, Ezziddin S.
Superior Response of CAP-PRRT of G3 NET When Switching to the Somatostatin Receptor Antagonist LM3: Intraindividual Proof-of-concept. 
Clin Nucl Med. 2025 Apr 30. doi: 10.1097/RLU.0000000000005938. Epub ahead of print. PMID: 40302124.

17. Speicher T, Burgard C, Rosar F, Bastian M, Bartholomä M, Maus S, Ezziddin S.
Superior NET Targeting by Switch From Agonist to Antagonist-mediated Somatostatin Receptor Theranostics Allowing Successful (LM3-based) PRRT of Otherwise Precluded mNET: Intraindividual Proof-of-concept.
Clin Nucl Med. 2025 Apr 29. doi: 10.1097/RLU.0000000000005936. Epub ahead of print. PMID: 40296275.

18. Burgard C, Rosar F, Ezziddin S, Hamoud BH, Solomayer EF, Laschke MW, Constantin A, Bartholomä M. 
[68Ga]Ga-FAPI-04 PET/CT in a patient with endometriosis: a potential game changer? 
Eur J Nucl Med Mol Imaging. 2025 Apr 4. doi: 10.1007 s00259-025-07252-9. Epub ahead of print. PMID: 40183952.
Download PDF

19. Rosar F, Khreish F, Nagel LS, Blickle A, Burgard C, Petto S, Bastian MB, Speicher T, Bartholomä M, Maus S, Schaefer-Schuler A, Ezziddin S. 
225 Ac-PSMA-617 Augmentation After Insufficient Response Under 177 Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study). 
Clin Nucl Med. 2025 Apr 1;50(4):e202-e206. doi: 10.1097/RLU.0000000000005640. Epub 2024 Dec 31. PMID: 39787407.

20. Bastian MB, Sieben M, Blickle A, Burgard C, Speicher T, Bartholomä M, Schaefer-Schuler A, Maus S, Ezziddin S, Rosar F. 
Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia.
Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1271-1277. doi: 10.1007/s00259-024-07006-z. Epub 2024 Dec 3. PMID: 39625666; PMCID: PMC11839894.
Download PDF

21. Speicher T, Bastian MB, Christofyllakis K, Rosar F, Ezziddin S, Burgard C.
[18F]FDG PET/CT of Langerhans Cell Histiocytosis with Vertebra Plana.
Diagnostics (Basel). 2025 Mar 28;15(7):862. doi: 10.3390/diagnostics15070862. PMID: 40218211; PMCID: PMC11988986.
Download PDF

22. Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, Sonni I, Rettig MB, Rosar F, Ezziddin S, Denis CS, de Kouchkovsky I, Aggarwal R, Emmett L, Hope TA, Czernin J, Calais J. 
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. 
Eur J Nucl Med Mol Imaging. 2025 Mar 26. doi: 10.1007/s00259-025-07178-2. Epub ahead of print. PMID: 40137974.

23. Aouf A, Speicher T, Blickle A, Bastian MB, Burgard C, Rosar F, Ezziddin S, Sabet A. 
Prediction of lesion-based response to PRRT using baseline somatostatin receptor PET. 
Front Med (Lausanne). 2025 Mar 14;12:1523862. doi: 10.3389/fmed.2025.1523862. PMID: 40160333; PMCID: PMC11949938.
Download PDF

24. Abdlkadir AS, Rosar F, Jalilian A, Moghrabi S, Al-Balooshi B, Rabei O, Kairemo K, Al-Ibraheem A.
Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review. 
Nucl Med Mol Imaging. 2025 Feb;59(1):50-61. doi: 10.1007/s13139-024-00891-0. Epub 2024 Nov 12. PMID: 39881968; PMCID: PMC11772629.

25. Bastian MB, Sieben M, Burgard C, Blickle A, Speicher T, Bartholomä M, Maus S, Petto S, Schaefer-Schuler A, Ezziddin S, Rosar F. 
Outcome and Renal Safety of PSMA-Targeted Radioligand Therapy in mCRPC Patients With Preexisting Impaired Renal Function.
Clin Nucl Med. 2025 Feb 1;50(2):165-171. doi: 10.1097/RLU.0000000000005583. Epub 2024 Nov 27. PMID: 39601036.

26. Bastian MB, Burgard C, Blickle A, Ezziddin S, Rosar F. 
Diffuse Peritoneal Carcinomatosis of Prostate Cancer Unveiled by [89Zr]Zr-PSMA-617 PET/CT. 
Clin Nucl Med. 2025 Feb 1;50(2):191-192. doi: 10.1097/RLU.0000000000005604. Epub 2024 Nov 26. PMID: 39774158.

27. Speicher T, Burgard C, Bastian M, Rosar F, Bartholomä M, Maus S, Ezziddin S.
First Successful In-Human Application of 225Ac-DOTA-LM3 Mono-PRRT for the Treatment of an Otherwise Therapy-Resistant Neuroendocrine Tumor (NET G3).
Clin Nucl Med. 2025 Jan 1;50(1):101-102. doi: 10.1097/RLU.0000000000005439. PMID: 39626292.

1: Rosar F, Khreish F, Nagel LS, Blickle A, Burgard C, Petto S, Bastian MB, Speicher T, Bartholomä M, Maus S, Schaefer-Schuler A, Ezziddin S. 
225Ac-PSMA-617 Augmentation After Insufficient Response Under 177Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study).
Clin Nucl Med. 2024 Dec 31. doi: 10.1097/RLU.0000000000005640. Epub ahead of print. PMID: 39787407.

2: Martin S, Schreck MV, Stemler T, Maus S, Rosar F, Burgard C, Schaefer-Schuler A, Ezziddin S, Bartholomä MD. 
Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform. 
EJNMMI Radiopharm Chem. 2024 Dec 11;9(1):84. doi: 10.1186/s41181-024-00314-7. PMID: 39661209; PMCID: PMC11635053.
Download PDF

3: Thurner L, Melivadze K, Matschke J, Topalidis T, Bachhuber A, Speicher T, Rosar F, Reischl U, Tränkenschuh W, Friesenhahn-Ochs B, Fries P, Becker SL, Fleser O. 
Challenging granulomatous differential diagnosis of CNS lesions in a 75-year-old patient with indolent lymphoma. 
Front Immunol. 2024 Dec 4;15:1462310. doi: 10.3389/fimmu.2024.1462310. PMID: 39697334; PMCID: PMC11652532.
Download PDF

4: Bastian MB, Sieben M, Blickle A, Burgard C, Speicher T, Bartholomä M, Schaefer-Schuler A, Maus S, Ezziddin S, Rosar F. 
Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia.
Eur J Nucl Med Mol Imaging. 2024 Dec 3. doi: 10.1007/s00259-024-07006-z. Epub ahead of print. PMID: 39625666.
Download PDF

5: Bastian MB, Sieben M, Burgard C, Blickle A, Speicher T, Bartholomä M, Maus S, Petto S, Schaefer-Schuler A, Ezziddin S, Rosar F. 
Outcome and Renal Safety of PSMA-Targeted Radioligand Therapy in mCRPC Patients With Preexisting Impaired Renal Function.
Clin Nucl Med. 2025 Feb 1;50(2):165-171. doi: 10.1097/RLU.0000000000005583. Epub 2024 Nov 27. PMID: 9601036.

6: Bastian MB, Burgard C, Blickle A, Ezziddin S, Rosar F. 
Diffuse Peritoneal Carcinomatosis of Prostate Cancer Unveiled by [89Zr]Zr-PSMA-617 PET/CT. 
Clin Nucl Med. 2025 Feb 1;50(2):191-192. doi: 10.1097/RLU.0000000000005604. Epub 2024 Nov 26. PMID: 9774158.

7: Abdlkadir AS, Rosar F, Jalilian A, Moghrabi S, Al-Balooshi B, Rabei O, Kairemo K, Al-Ibraheem A. 
Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review. 
Nucl Med Mol Imaging. 2025 Feb;59(1):50-61. doi: 10.1007/s13139-024-00891-0. Epub 2024 Nov 12. PMID: 9881968; PMCID: PMC11772629.

8: Burgard C, Khreish F, Dahlmanns L, Blickle A, Bastian MB, Speicher T, Maus S, Schaefer-Schuler A, Bartholomä M, Petto S, Ezziddin S, Rosar F. 
Analysis of Molecular Imaging Biomarkers Derived from [¹⁸F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [²²⁵Ac]Ac-PSMA-617-Augmented [¹⁷⁷Lu]Lu-PSMA-617
Radioligand Therapy. Cancers (Basel). 2024 Oct 19;16(20):3532. doi: 10.3390/cancers16203532. PMID: 39456626; PMCID: PMC11506772.
Download PDF

9: Bastian MB, Burgard C, Blickle A, Speicher T, Ezziddin S, Rosar F.
[⁸⁹Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [¹⁸F]PSMA-1007 Imaging.
Diagnostics (Basel). 2024 Oct 18;14(20):2321. doi: 10.3390/diagnostics14202321. PMID: 39451644; PMCID: PMC115066699
Download PDF

10: Brust LA, Höh M, Linxweiler M, Bozzato A, Burgard C, Rosar F, Altmeyer K, Lessenich CP, Kohlwes E, Pillong L. 
Cutting the Gordian Knot: Rare Presentation of Nodular Fasciitis as Supraclavicular Swelling with Muscular Involvement in ⁶⁸Ga-FAPI-PET/CT.
Diagnostics (Basel). 2024 Oct 8;14(19):2238. doi: 10.3390/diagnostics14192238. PMID: 39410642; PMCID: PMC11475205.
Download PDF

11: Burgard C, Rosar F, Larsen E, Khreish F, Linxweiler J, Marlowe RJ, Schaefer-Schuler A, Maus S, Petto S, Bartholomä M, Ezziddin S. 
Outstanding increase in tumor-to-background ratio over time allows tumor localization by [⁸⁹Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer.
Cancer Imaging. 2024 Oct 7;24(1):132. doi: 10.1186/s40644-024-00778-5. PMID: 39375762. 
Download PDF

12: Hierlmeier I, Marino N, Schreck MV, Schneider L, Maus S, Barrett K, Kretowicz M, Engle JW, Pierri G, Ezziddin S, Bartholomä MD. 
Radiochemistry and Complex Formation of the Cyclen-Derived Chelator DOTI-Me with Mn²⁺, Cu²⁺, Zn²⁺, Ga³⁺, In³⁺, Tb³⁺, and Lu³⁺
Inorg Chem. 2024 Oct 1. doi: 10.1021/acs.inorgchem.4c03571. Epub ahead of print. PMID: 39352711.

13: Bastian MB, Rosar F, Burgard C, Blickle A, Ezziddin S. 
Ectopic Cushing Syndrome Localized by 68Ga-DOTA-LM3 PET/CT. 
Clin Nucl Med. 2024 Aug 28. doi: 10.1097/RLU.0000000000005408. Epub ahead of print. PMID: 39207826.

14: Hein C,Burgard C, Blickle A, Bastian MB, Maus S, Schaefer-Schuler A, Hoffmann MA, Schreckenberger M, Ezziddin S, Rosar F. 
Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival.
Cancers (Basel). 2024 Jul 26;16(15):2670. doi: 10.3390/cancers16152670. PMID: 39123398; PMCID: PMC11311702.
Download PDF

15: Rosar F, Schuler J, Burgard C, Blickle A, Bartholomä M, Maus S, Petto S, Khreish F, Schaefer A, Ezziddin S. 
Efficacy and safety of rechallenge [¹⁷⁷Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).
Eur J Nucl Med Mol Imaging. 2024 Jul 15. doi: 10.1007/s00259-024-06825-4. Epub ahead of print. PMID: 39008067.
Download PDF

16: Rosar F, Burgard C, Rohloff LV,Blickle A, Bartholomä M, Maus S, Petto S, Schaefer-Schuler A, Ezziddin S. 
225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective Registry.
Clin Nucl Med. 2024 Jul 1;49(7):621-629. doi: 10.1097/RLU.0000000000005253. Epub 2024 May 21. PMID: 38769643.

17: Rosar F, Burgard C, David S, Marlowe RJ, Bartholomä M, Maus S, Petto S, Khreish F, Schaefer-Schuler A, Ezziddin S. 
Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT. 
Sci Rep. 2024 May 17;14(1):11271. doi: 10.1038/s41598-024-61961-z. PMID: 38760451; PMCID: PMC11101421.

18: Bastian MB, Blickle A, Burgard C, Fleser O, Christofyllakis K, Ezziddin S, Rosar F. 
Histopathological Confirmed Polycythemia Vera with Transformation to Myelofibrosis Depicted on [¹⁸F]FDG PET/CT. 
Diagnostics (Basel). 2024 May 8;14(10):982. doi: 10.3390/diagnostics14100982. PMID: 38786281; PMCID: PMC11120594.
Download PDF

19: Rosar F, Ezziddin S, Bittenbring JT, Christofyllakis K, Burgard C. 
Mast Cell Sarcoma Mimicking Lymphoma or Metastatic Disease on 18 F-FDG PET/CT. 
Clin Nucl Med. 2024 May 1;49(5):464-465. doi: 10.1097/RLU.0000000000005162. Epub 2024 Mar 7. PMID: 38456450.

20: Markandu S, Blickle A, Burgard C, Remke M, Altmeyer K, Wagner M, Ezziddin S, Rosar F. 
Mind the Pitfall: Solitary Nodular Fasciitis Mimicking Extra-Nodal Manifestation of Hodgkin Lymphoma on [¹⁸F]FDG PET/CT. 
Diagnostics (Basel). 2024 Apr 9;14(8):783. doi: 10.3390/diagnostics14080783. PMID: 38667429; PMCID: PMC11049122.
Download PDF

21: Khreish F, Schaefer-Schuler A, Roth L, Burgard C, Rosar F, Ezziddin S. 
Concomitant lithium increases radioiodine uptake and absorbed doses per administered activity in graves' disease: comparison of conventional versus lithium-augmented radioiodine therapy.
Front Med (Lausanne). 2024 Apr 5;11:1382024. doi: 10.3389/fmed.2024.1382024. PMID: 38646563; PMCID: PMC11026544.
Download PDF

22: Schaefer-Schuler A, Burgard C, Blickle A, Maus S, Petrescu C, Petto S, Bartholomä M, Stemler T, Ezziddin S, Rosar F. 
[¹⁶¹Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [¹⁷⁷Lu]Lu-PSMA-617.
Theranostics. 2024 Feb 24;14(5):1829-1840. doi: 10.7150/thno.92273. PMID: 38505615; PMCID: PMC10945337.
Download PDF

23: Rosar F, Burgard C, Larsen E, Khreish F, Marlowe RJ, Schaefer-Schuler A, Maus S, Petto S,Bartholomä M, Ezziddin S. 
[⁸⁹Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [⁶⁸Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
Cancer Imaging. 2024 Feb 22;24(1):27. doi: 10.1186/s40644-024-00671-1. PMID: 38389092; PMCID: PMC10885487.
Download PDF

24: Burgard C, Hein C,Blickle A, Bartholomä M, Maus S, Petto S, Schaefer- Schuler A, Ezziddin S, Rosar F. 
Change in total lesion PSMA (TLP) during [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry.
Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):885-895. doi: 10.1007/s00259-023-06476-x. Epub 2023 Oct 27. PMID: 37889298; PMCID: PMC10796576.
Download PDF

25: Grawe F, Blom F, Winkelmann M, Burgard C, Schmid-Tannwald C, Unterrainer LM, Sheikh GT, Pfitzinger PL, Kazmierczak P, Cyran CC, Ricke J, Stief CG, Bartenstein P, Ruebenthaler J, Fabritius MP, Geyer T. 
Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients. 
Eur Radiol. 2024 Feb;34(2):1157-1166. doi: 10.1007/s00330-023-10083-7. Epub 2023 Aug 25. PMID: 37624414; PMCID: PMC10853294.
Download PDF

26: Burgard C, Engler J, Blickle A, Bartholomä M, Maus S, Schaefer-Schuler A, Khreish F, Ezziddin S, Rosar F. 
Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker.
Front Med (Lausanne). 2024 Jan 17;10:1339160. doi: 10.3389/fmed.2023.1339160. PMID: 38298510; PMCID: PMC10827880.
Download PDF

27: Bellendorf A, Mader N, Mueller SP, Ezziddin S, Bockisch A, Grafe H, Best J, Goebel J, Pöppel TD, Sabet A. 
Safety and Efficacy of Selective Internal Radionuclide Therapy with ⁹⁰Y Glass Microspheres in Patients with Progressive Hepatocellular Carcinoma after the Failure of Repeated Transarterial Chemoembolization.
Pharmaceuticals (Basel). 2024 Jan 11;17(1):101. doi: 10.3390/ph17010101. PMID: 38256934; PMCID: PMC10819448.
Download PDF

1: Klamminger GG, Burgard C, Rosar F, Altmeyer K, Malinowski M, Nigdelis MP, Stahl PR, Solomayer EF, Haj Hamoud B. 
Unusual Case of Splenic Metastasis in Adenosquamous Carcinoma of the Cervix Uteri: Diagnosis and Treatment Considerations.
Am J Case Rep. 2023 Dec 8;24:e941600. doi: 10.12659/AJCR.941600. PMID: 38062677; PMCID: PMC10720923.
Download PDF

2: Hierlmeier I, Guillou A, Earley DF, Linden A, Holland JP, Bartholomä MD.
HNODThia: A Promising Chelator for the Development of ⁶⁴Cu Radiopharmaceuticals. 
Inorg Chem. 2023 Dec 18;62(50):20677-20687. doi: 10.1021/acs.inorgchem.3c01616. Epub 2023 Jul 24. PMID: 37487036.

3: Rosar F, Burgard C, Gargiulo R, Ezziddin S. 
Active Lumbar Spondylodiscitis on [⁶⁸Ga]Ga-PSMA-11 PET/CT Mimicking Bone Metastasis. 
Diagnostics (Basel). 2023 Dec 7;13(24):3616. doi: 10.3390/diagnostics13243616. PMID: 38132199; PMCID: PMC10742755.
Download PDF

4: Schreck MV, Burgard C, Schmidtke A, Hierlmeier I, Stemler T, Maus S, Rosar F, Jung M, Speicher A, Ezziddin S, Holland JP, Bartholomä MD. 
Radiometal Complexes as Pharmacokinetic Modifiers: A Potent ⁶⁸Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me.
Mol Pharm. 2023 Dec 4;20(12):6463-6473. doi: 10.1021/acs.molpharmaceut.3c00852. Epub 2023 Nov 18. PMID: 37978936.

5: Hoffmann MA, Knoll SN, Baqué PE, Rosar F, Scharrer I, Reuss S, Schreckenberger M. 
The Influence of Hypothyroid Metabolic Status on Blood Coagulation and the Acquired von Willebrand Syndrome. 
J Clin Med. 2023 Sep 11;12(18):5905. doi: 10.3390/jcm12185905. PMID: 37762844; PMCID: PMC10532367.
Download PDF

6: Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. 
Joint EANM/SNMMI procedure guideline for the use of ¹⁷⁷Lu-labeled PSMA-targeted radioligand-therapy (¹⁷⁷Lu-PSMA-RLT). 
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29. PMID: 37246997; PMCID: PMC10317889.
Download PDF

7: Rosar F, Khreish F, Marlowe RJ, Schaefer-Schuler A, Burgard C, Maus S, Petto S, Bartholomä M, Ezziddin S. 
Detection efficacy of [⁸⁹Zr]Zr-PSMA-617 PET/CT in [⁶⁸Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer.
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2899-2909. doi: 10.1007/s00259-023-06241-0. Epub 2023 May 6. PMID: 37148297; PMCID: PMC10317886.
Download PDF

8: Burgard C, Rosar F, Marlowe RJ, Bartholomä M, Dewes S, Schaefer-Schuler A, Linxweiler J, Khreish F, Ezziddin S. 
Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration- Resistant Prostate Cancer: Intra-Individual Evaluations.
Cancers (Basel). 2023 May 3;15(9):2592. doi: 10.3390/cancers15092592. PMID: 37174058; PMCID: PMC10177482.
Download PDF

9: Rosar F, Maus S, Schaefer-Schuler A, Burgard C, Khreish F, Ezziddin S. 
New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC. 
Clin Nucl Med. 2023 May 1;48(5):433-434. doi: 10.1097/RLU.0000000000004589. Epub 2023 Feb 8. PMID: 36758550.

10: Rosar F, Burgard C, Linxweiler J, Wagner M, Ezziddin S. 
Histologically Confirmed Testicular Metastasis Revealed by [⁸⁹Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging.
Diagnostics (Basel). 2023 Apr 5;13(7):1352. doi: 10.3390/diagnostics13071352. PMID: 37046570; PMCID: PMC10093488.
Download PDF

11: Burgard C, Hoffmann MA, Frei M, Buchholz HG, Khreish F, Marlowe RJ, Schreckenberger M, Ezziddin S, Rosar F. 
Detection Efficacy of ⁶⁸Ga- PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center "Real-World" Experience.
Cancers (Basel). 2023 Feb 21;15(5):1376. doi: 10.3390/cancers15051376. PMID: 36900169; PMCID: PMC10000220.
Download PDF

1: Banda A, Privé BM, Allach Y, Uijen MJM, Peters SMB, Loeff CC, Gotthardt M, Muselaers CHJ, Witjes JA, van Oort IM, Sedelaar JPM, Westdorp H, Mehra N, Khreish F, Ezziddin S, Sabet A, Kreissl MC, Winkens T, Seifert P, Janssen MJR, van Gemert WAM, Nagarajah J. 
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study. 
Cancers (Basel). 2022 Dec 31;15(1):297. doi: 10.3390/cancers15010297. PMID: 36612293; PMCID: PMC9818570.
Download PDF

2: Rosar F, Schaefer-Schuler A, Bartholomä M, Maus S, Petto S, Burgard C, Privé BM, Franssen GM, Derks YHW, Nagarajah J, Khreish F, Ezziddin S. 
[⁸⁹Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates. 
Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4736-4747. doi: 10.1007/s00259-022-05925-3. Epub 2022 Aug 5. PMID: 35930033; PMCID: PMC9606102.
Download PDF

3: Rosar F, Hügle MJ, Ries M, Bartholomä M, Maus S, Fries P, Khreish F, Ezziddin S. 
Benefit of including CT urography in [68Ga]PSMA-11 PET/CT with low- dose CT: first results from a larger prostate cancer cohort analysis.
Q J Nucl Med Mol Imaging. 2022 Sep;66(3):280-289. doi: 10.23736/S1824-4785.20.03224-0. Epub 2020 Jan 24. PMID: 31992688.

4: Hoffmann MA, Müller-Hübenthal J, Rosar F, Fischer N, von Eyben FE, Buchholz HG, Wieler HJ, Schreckenberger M. 
Primary Staging of Prostate Cancer Patients with [¹⁸F]PSMA-1007 PET/CT Compared with [⁶⁸Ga]Ga-PSMA-11 PET/CT. 
J Clin Med. 2022 Aug 29;11(17):5064. doi: 10.3390/jcm11175064. PMID: 36078994; PMCID: PMC9457380.
Download PDF

5: Rosar F, Burgard C, Linxweiler M, Stahl PR, Khreish F, Ezziddin S. 
Strongly Radioiodine-Positive Pancreatic Adenocarcinoma Mimicking Metastasis of Differentiated Thyroid Cancer. 
Diagnostics (Basel). 2022 Aug 11;12(8):1934. doi: 10.3390/diagnostics12081934. PMID: 36010284; PMCID: PMC9406392.
Download PDF

6: Marlin A, Hierlmeier I, Guillou A, Bartholomä M, Tripier R, Patinec V.
Bioconjugated chelates based on (methylpyridinyl)tacn: synthesis, 64Cu labeling and in vitro evaluation for prostate cancer targeting. 
Metallomics. 2022 Jun 24;14(6):mfac036. doi: 10.1093/mtomcs/mfac036. PMID: 35648482.
Download PDF

7: Rosar F, Bader H, Bartholomä M, Maus S, Burgard C, Linxweiler J, Khreish F, Ezziddin S. 
Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure-Preliminary Evidence of Pilot Experience. 
Cancers (Basel). 2022 May 29;14(11):2691. doi: 10.3390/cancers14112691. PMID: 35681671; PMCID: PMC9179420.
Download PDF

8: Rosar F, Burgard C, Neubert C, Stahl PR, Khreish F, Ezziddin S. 
PSMA- Positive Follicular Thyroid Carcinoma Incidentally Detected by [⁶⁸Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression. 
Diagnostics (Basel). 2022 May 12;12(5):1211. doi: 10.3390/diagnostics12051211. PMID: 35626366; PMCID: PMC9139808.
Download PDF

9: Rosar F, Bartholomä M, Maus S, Privé BM, Khreish F, Franssen GM, Derks YHW, Nagarajah J, Ezziddin S. 
89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CT. 
Clin Nucl Med. 2022 May 1;47(5):435-436. doi: 10.1097/RLU.0000000000004108. PMID: 35234197.

10: Rosar F, Neher R, Burgard C, Linxweiler J, Schreckenberger M, Hoffmann MA, Bartholomä M, Khreish F, Ezziddin S. 
Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC. 
Cancers (Basel). 2022 Mar 26;14(7):1696. doi: 10.3390/cancers14071696. PMID: 35406467; PMCID: PMC8997007.
Download PDF

11: Hoffmann MA, von Eyben FE, Fischer N, Rosar F, Müller-Hübenthal J, Buchholz HG, Wieler HJ, Schreckenberger M. 
Comparison of [¹⁸F]PSMA-1007 with [⁶⁸Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse. 
Cancers (Basel). 2022 Mar 14;14(6):1479. doi: 10.3390/cancers14061479. PMID: 35326629; PMCID: PMC8946234.
Download PDF

12: Burgard C, Rosar F, Khreish F, Ezziddin S. 
Systemic Mastocytosis Treatment with Midostaurin: [¹⁸F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome. 
Diagnostics (Basel). 2022 Mar 10;12(3):680. doi: 10.3390/diagnostics12030680. PMID: 35328232; PMCID: PMC8947295.
Download PDF

13: Privé BM, Slootbeek PHJ, Laarhuis BI, Naga SP, van der Doelen MJ, van Kalmthout LWM, de Keizer B, Ezziddin S, Kratochwil C, Morgenstern A, Bruchertseifer F, Ligtenberg MJL, Witjes JA, van Oort IM, Gotthardt M, Heskamp S, Janssen MJR, Gerritsen WR, Nagarajah J, Mehra N. 
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. 
Prostate Cancer Prostatic Dis. 2022 Mar;25(1):71-78. doi: 10.1038/s41391-021-00424-2. Epub 2021 Jul 12. PMID: 34253846.

14: Sartor O, Fougère C, Essler M, Ezziddin S, Kramer G, Ellinger J, Nordquist L, Sylvester J, Paganelli G, Peer A, Bögemann M, Meltzer J, Sandström P, Verholen F, Song DY. 
¹⁷⁷Lu-Prostate-Specific Membrane Antigen Ligand After ²²³Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience. 
J Nucl Med. 2022 Mar;63(3):410-414. doi: 10.2967/jnumed.121.262240. Epub 2021 Jun 24. Erratum in: J Nucl Med. 2022 Jul;63(7):100-1000. PMID: 34168015; PMCID: PMC8978191.
Download PDF

15: Privé BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, Bartholomä M, Maus S, Gotthardt M, Laverman P, Konijnenberg MW, Ezziddin S, Nagarajah J, Heskamp S. 
⁸⁹Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. 
Eur J Nucl Med Mol Imaging. 2022 May;49(6):2064-2076. doi: 10.1007/s00259-021-05661-0. Epub 2021 Dec 21. PMID: 34932154.

16: Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, Schreckenberger M, Bartholomä M, Ezziddin S. 
Early molecular imaging response assessment based on determination of total viable tumor burden in [⁶⁸Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy. 
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1584-1594. doi: 10.1007/s00259-021-05594-8. Epub 2021 Nov 2. PMID: 34725725; PMCID: PMC8940840.
Download PDF

17: Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, Linxweiler J, Bartholomä M, Ezziddin S. 
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1075-1085. doi: 10.1007/s00259-021-05525-7. Epub 2021 Sep 7. PMID: 34494131; PMCID: PMC8803625.
Download PDF

1: Sabet A, Mader N, Bittenbring JT, Khreish F, Grünwald F, Biersack HJ, Ezziddin S. 
Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE.
Pharmaceuticals (Basel). 2021 Oct 5;14(10):1022. doi: 10.3390/ph14101022. PMID: 34681247; PMCID: PMC8539404.
Download PDF

2: Stemler T, Hoffmann C, Hierlmeier IM, Maus S, Krause E, Ezziddin S, Jung G, Bartholomä MD. 
A Structure-Activity Relationship Study of Bimodal BODIPY-Labeled PSMA-Targeting Bioconjugates.
ChemMedChem. 2021 Aug 19;16(16):2535-2545. doi: 10.1002/cmdc.202100210. Epub 2021 May 24. PMID: 33905162; PMCID: PMC8453963.
Download PDF

3: Khreish F, Ribbat K, Bartholomä M, Maus S, Stemler T, Hierlmeier I, Linxweiler J, Schreckenberger M, Ezziddin S, Rosar F. 
Value of Combined PET Imaging with [¹⁸F]FDG and [⁶⁸Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [¹⁷⁷Lu]Lu-PSMA-617 RLT.
Cancers (Basel). 2021 Aug 17;13(16):4134. doi: 10.3390/cancers13164134. PMID: 34439287; PMCID: PMC8391978.
Download PDF

4: Khreish F, Wiessner M, Rosar F, Ghazal Z, Sabet A, Maus S, Linxweiler J, Bartholomä M, Ezziddin S. 
Response Assessment and Prediction of Progression-Free Survival by ⁶⁸Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing ¹⁷⁷Lu-PSMA-617 Radioligand Therapy.
Biomolecules. 2021 Jul 26;11(8):1099. doi: 10.3390/biom11081099. PMID: 34439768; PMCID: PMC8391209.
Download PDF

5: Linxweiler J, Sprenk J, Cascetta K, Pryalukhin A, Hölters S, Zeuschner P, Nini A, Al-Kailani Z, Ezziddin S, Bohle RM, Fries P, Ohlmann CH, Heinzelbecker J, Siemer S, Stöckle M, Junker K, Saar M. 
Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
J Urol. 2021 Jul;206(1):88-96. doi: 10.1097/JU.0000000000001697. Epub 2021 Feb 22. PMID: 33617326.

6: Rosar F, Kochems N, Bartholomä M, Maus S, Stemler T, Linxweiler J, Khreish F, Ezziddin S. 
Renal Safety of [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function.
Cancers (Basel). 2021 Jun 21;13(12):3095. doi: 10.3390/cancers13123095. PMID: 34205686; PMCID: PMC8235711.
Download PDF

7: Rosar F, Krause J, Bartholomä M, Maus S, Stemler T, Hierlmeier I, Linxweiler J, Ezziddin S, Khreish F. 
Efficacy and Safety of [²²⁵Ac]Ac-PSMA-617 Augmented [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis.
Pharmaceutics. 2021 May 14;13(5):722. doi: 10.3390/pharmaceutics13050722. PMID: 34069003; PMCID: PMC8156464.
Download PDF

8: Rosar F, Schön N, Bohnenberger H, Bartholomä M, Stemler T, Maus S, Khreish F, Ezziddin S, Schaefer-Schuler A. 
Comparison of different methods for post- therapeutic dosimetry in [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy.
EJNMMI Phys. 2021 May 5;8(1):40. doi: 10.1186/s40658-021-00385-4. PMID: 33950333; PMCID: PMC8099965.
Download PDF

9: Martin S, Tönnesmann R, Hierlmeier I, Maus S, Rosar F, Ruf J, Holland JP, Ezziddin S, Bartholomä MD. 
Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [¹⁷⁷Lu]Lu-PSMA-617.
J Med Chem. 2021 Apr 22;64(8):4960-4971. doi: 10.1021/acs.jmedchem.1c00045. Epub 2021 Apr 7. PMID: 33826320.

10: Rosar F, Bohnenberger H, Moon ES, Rösch F, Denig A, Vincenz-Zörner D, Hoffmann MA, Khreish F, Ezziddin S, Schreckenberger M, Buchholz HG, Schaefer- Schuler A. 
Impact of prompt gamma emission of ⁴⁴Sc on quantification in preclinical and clinical PET systems.
Appl Radiat Isot. 2021 Apr;170:109599. doi: 10.1016/j.apradiso.2021.109599. Epub 2021 Jan 21. PMID: 33515928.
Download PDF

11: Rosar F, Hau F, Bartholomä M, Maus S, Stemler T, Linxweiler J, Ezziddin S, Khreish F. 
Molecular imaging and biochemical response assessment after a single cycle of [²²⁵Ac]Ac-PSMA-617/[¹⁷⁷Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [¹⁷⁷Lu]Lu-PSMA-617 monotherapy.
Theranostics. 2021 Feb 16;11(9):4050-4060. doi: 10.7150/thno.56211. PMID: 33754047; PMCID: PMC7977444.
Download PDF

12: Martin S, Maus S, Stemler T, Rosar F, Khreish F, Holland JP, Ezziddin S, Bartholomä MD. 
Proof-of-Concept Study of the NOTI Chelating Platform: Preclinical Evaluation of ⁶⁴Cu-Labeled Mono- and Trimeric c(RGDfK) Conjugates.
Mol Imaging Biol. 2021 Feb;23(1):95-108. doi: 10.1007/s11307-020-01530-8. Epub 2020 Aug 27. PMID: 32856224; PMCID: PMC7782405.
Download PDF

13: Helmberger T, Golfieri R, Pech M, Pfammatter T, Arnold D, Cianni R, Maleux G, Munneke G, Pellerin O, Peynircioglu B, Sangro B, Schaefer N, de Jong N, Bilbao JI; On behalf of the CIRT Steering Committee; On behalf of the CIRT Principal Investigators. 
Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
Cardiovasc Intervent Radiol. 2021 Jan;44(1):21-35. doi: 10.1007/s00270-020-02642-y. Epub 2020 Sep 21. PMID: 32959085; PMCID: PMC7728645.
Download PDF

14: Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, Saar M, Bartholomä M, Ezziddin S. 
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy.
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):103-112. doi: 10.1007/s00259-020-04828-5. Epub 2020 May 6. PMID: 32378019.

1: Thurner L, Bewarder M, Rosar F, Orth P, Meuter RB, Rixecker T, Lesan V, Kohn DM, Schneider G, Baumhoer D, Bohle RM, Veith C, Bittenbring JT. 
Indeterminate Dendritic Cell Tumor With Persistent Complete Metabolic Response to BRAF/MEK Inhibition. 
Hemasphere. 2020 Dec 9;5(1):e511. doi: 10.1097/HS9.0000000000000511. PMID: 33324955; PMCID: PMC7732267.
Download PDF

2: Rosar F, Pauly P, Ries M, Schaefer-Schuler A, Maus S, Schreckenberger M, Khreish F, Ezziddin S. 
Determination of split renal function by PSMA imaging: comparison of ⁶⁸Ga-PSMA-11 PET with ^99mTc-MAG3 scintigraphy. 
Am J Nucl Med Mol Imaging. 2020 Oct 15;10(5):249-256. PMID: 33224621; PMCID: PMC7675112.
Download PDF

3: Stögbauer J, Rosar F, Dillmann U, Faßbender K, Ezziddin S, Spiegel J. 
Striatal dopamine transporters and cognitive function in Parkinson's disease. 
Acta Neurol Scand. 2020 Oct;142(4):385-391. doi: 10.1111/ane.13320. Epub 2020 Aug 5. PMID: 32914881.
Download PDF

4: Hoffmann MA, Buchholz HG, Wieler HJ, Rosar F, Miederer M, Fischer N, Schreckenberger M. 
Dual-Time Point [⁶⁸Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer. 
Cancers (Basel). 2020 Sep 28;12(10):2788. doi: 10.3390/cancers12102788. PMID: 32998432; PMCID: PMC7600341.
Download PDF

5: Khreish F, Rosar F, Kratochwil C, Giesel FL, Haberkorn U, Ezziddin S. 
Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease. 
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):2040-2041. doi: 10.1007/s00259-019-04623-x. Epub 2019 Dec 9. PMID: 31814067.

6: Rosar F, Ribbat K, Ries M, Linxweiler J, Bartholomä M, Maus S, Schreckenberger M, Ezziddin S, Khreish F. 
Neuron-specific enolase has potential value as a biomarker for [¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients.
EJNMMI Res. 2020 May 24;10(1):52. doi: 10.1186/s13550-020-00640-2. PMID: 32449086; PMCID: PMC7246282.
Download PDF

7: Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, Tosch M, Hehr T, Eschmann SM, Bultel YP, Hass P, Fleckenstein J, Thieme A, Stockinger M, Dieckmann K, Miederer M, Holl G, Rischke HC, Gkika E, Adebahr S, König J, Grosu AL; 
PET-Plan study group. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020 Apr;21(4):581-592. doi: 10.1016/S1470-2045(20)30013-9. Epub 2020 Mar 12. PMID: 32171429.

8: Rosar F, Buchholz HG, Michels S, Hoffmann MA, Piel M, Waldmann CM, Rösch F, Reuss S, Schreckenberger M. 
Image quality analysis of ⁴⁴Sc on two preclinical PET scanners: a comparison to ⁶⁸Ga. 
EJNMMI Phys. 2020 Mar 12;7(1):16. doi: 10.1186/s40658-020-0286-3. PMID: 32166581; PMCID: PMC7067939.
Download PDF

9: Rosar F, Ries M, Khreish F, Ezziddin S. 
Remember the Pitfall: Intrapancreatic Accessory Spleen Mimicking Neuroendocrine Neoplasm. 
Clin Nucl Med. 2020 Mar;45(3):250-251. doi: 10.1097/RLU.0000000000002945. PMID: 31977492.

10: Rosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, Bohnenberger H, Linxweiler J, Bartholomä M, Ohlmann C, Ezziddin S. 
New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):687-694. doi: 10.1007/s00259-019-04674-0. Epub 2020 Jan 3. PMID: 31901103.

11: Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, Stemler T, Saar M, Bartholomä M, Ezziddin S. 
²²⁵Ac-PSMA-617/¹⁷⁷Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. 
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):721-728. doi: 10.1007/s00259-019-04612-0. Epub 2019 Nov 22. PMID: 31758224.

12: Hoffmann MA, Buchholz HG, Wieler HJ, Miederer M, Rosar F, Fischer N, Müller- Hübenthal J, Trampert L, Pektor S, Schreckenberger M. 
PSA and PSA Kinetics Thresholds for the Presence of ⁶⁸Ga-PSMA-11 PET/CT-Detectable Lesions in Patients With Biochemical Recurrent Prostate Cancer.
Cancers (Basel). 2020 Feb 8;12(2):398. doi: 10.3390/cancers12020398. PMID: 32046318; PMCID: PMC7072299.

1: Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. 
EANM procedure guidelines for radionuclide therapy with ¹⁷⁷Lu-labelled PSMA-ligands (¹⁷⁷Lu-PSMA-RLT). 
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22. PMID: 31440799.

2: Schubert E, Dogan S, Dillmann U, Schaefer-Schuler A, Fassbender K, Ezziddin S, Spiegel J. 
MIBG scintigraphy of the major salivary glands in progressive supranuclear palsy and corticobasal degeneration. 
Parkinsonism Relat Disord. 2019 Sep;66:247-248. doi: 10.1016/j.parkreldis.2019.07.003. Epub 2019 Jul 6. PMID: 31300262.

3: Ries M, Khreish F, Berchem G, Ezziddin S. 
Recovery of Renal Function Under PSMA Mediated Radioligand Therapy of Advanced Metastasized Castration Resistant Prostate Cancer. 
Clin Nucl Med. 2019 Sep;44(9):730-731. doi: 10.1097/RLU.0000000000002704. PMID: 31283606.

4: Sabet A, Ries M, Al-Khalaf Y, Meyer C, Rudlowski C, Simon B, Khreish F, Ezziddin S. 
Early metabolic response assessment of breast cancer liver metastases: 4-week posttreatment FDG PET predicts survival after 90Y microsphere radioembolization. 
Nuklearmedizin. 2019 Jun;58(3):242-248. English. doi: 10.1055/a-0891-7650. Epub 2019 Jun 5. PMID: 31167272.

5: Dizdarevic S, Petersen PM, Essler M, Versari A, Bourre JC, la Fougère C, Valdagni R, Paganelli G, Ezziddin S, Kalinovský J, Bayh I, Du Y. 
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice.
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1102-1110. doi: 10.1007/s00259-019-4261-y. Epub 2019 Jan 12. PMID: 30637501; PMCID: PMC6451709.
Download PDF 

6: Michels S, Buchholz HG, Rosar F, Heinrich I, Hoffmann MA, Schweiger S, Tüscher O, Schreckenberger M. 
18F-FDG PET/CT: an unexpected case of Huntington's disease. 
BMC Neurol. 2019 May 1;19(1):78. doi: 10.1186/s12883-019-1311-9. PMID: 31043171; PMCID: PMC6495557.
Download PDF

7: Ries M, Khreish F, Veith C, von den Hoff J, Ezziddin S. 
Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer. 
Clin Nucl Med. 2019 Feb;44(2):153-154. doi: 10.1097/RLU.0000000000002359. PMID: 30371596.

8: Guillou A, Lima LMP, Esteban-Gómez D, Le Poul N, Bartholomä MD, Platas-Iglesias C, Delgado R, Patinec V, Tripier R.
Methylthiazolyl Tacn Ligands for Copper Complexation and Their Bifunctional Chelating Agent Derivatives for Bioconjugation and Copper-64 Radiolabeling: An Example with Bombesin.
Inorg Chem. 2019 Feb 18; 58(4):2669-2685. doi: 10.1021/acs.inorgchem.8b03280. Epub 2019 Jan 28. PMID: 30689368

1: Weinmann C, Holland JP, Läppchen T, Scherer H, Maus S, Stemler T, Bohnenberger H, Ezziddin S, Kurz P, Bartholomä MD. 
Optimized synthesis and indium complex formation with the bifunctional chelator NODIA-Me. 
Org Biomol Chem. 2018 Oct 17;16(40):7503-7512. doi: 10.1039/c8ob01981a. PMID: 30276385.

2: Im Namen aller Teilnehmer/innen am Deutschen NET-Registers; Authors; Kollaboratoren:. 
Neuroendokrine Neoplasien im deutschen NET-Register [Neuroendocrine Neoplasia within the German NET Registry]. 
Z Gastroenterol. 2018 Oct;56(10):1237-1246. German. doi: 10.1055/a-0661-6099. Epub 2018 Oct 10. PMID: 30304748.

3: Sangro B, Maini CL, Ettorre GM, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Sciuto R, Pizzi G, Lastoria S; 
European Network on Radioembolization with Yttrium-90 resin microspheres (ENRY). Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. 
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1721-1730. doi: 10.1007/s00259-018-3968-5. Epub 2018 Mar 7. PMID: 29516130; PMCID: PMC6097757.
Download PDF

4: Soboll L, Leppert D, Dillmann U, Schaefer-Schuler A, Fassbender K, Ezziddin S, Spiegel J. 
MIBG scintigraphy of the major salivary glands in multiple system atrophy. 
Parkinsonism Relat Disord. 2018 Aug;53:112-114. doi: 10.1016/j.parkreldis.2018.04.034. Epub 2018 May 4. PMID: 29752191.

5: Linxweiler J, Saar M, Al-Kailani Z, Janssen M, Ezziddin S, Stöckle M, Siemer S, Ohlmann CH. 
Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes. 
Surg Oncol. 2018 Jun;27(2):138-145. doi: 10.1016/j.suronc.2018.02.010. Epub 2018 Feb 24. PMID: 29937163.

6: Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS); Netzwerk Neuroendokrine Tumoren (NeT) e.V. (Patientenvertretung); Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e.V. (NET-sgh) (Patientenvertretung); Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO), und Arbeitsgemeinschaft Internistische Onkologie (AIO) der Deutschen Krebsgesellschaft e.V; Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie e.V. (DGAV); Deutsche Gesellschaft für Chirurgie (DGCH); Deutsche Gesellschaft für Endoskopie und Bildgebende Verfahren (DGEBV); Deutsche Gesellschaft für Nuklearmedizin e.V. (DGNM); Deutsche Gesellschaft für Innere Medizin (DGIM); Deutsche Gesellschaft für Endokrinologie (DGE); Deutsche Gesellschaft für Palliativmedizin e.V. (DGP); Deutsche Röntgengesellschaft e.V. (DRG); Deutsche Gesellschaft für Pathologie e.V./Bundesverband Deutscher Pathologen (DGP/BDP); Deutsche Gesellschaft für interventionelle Radiologie (DGiR); Authors; Collaborators:. 
S2k-Leitlinie Neuroendokrine Tumore [Practice guideline neuroendocrine tumors - AWMF-Reg. [021-27]. 
Z Gastroenterol. 2018 Jun;56(6):583-681. German. doi: 10.1055/a-0604-2924. Epub 2018 Jun 11. PMID: 29890561.
Download PDF

7: Handkiewicz-Junak D, Poeppel TD, Bodei L, Aktolun C, Ezziddin S, Giammarile F, Delgado-Bolton RC, Gabriel M. 
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. 
Eur J Nucl Med Mol Imaging. 2018 May;45(5):846-859. doi: 10.1007/s00259-018-3947-x. Epub 2018 Feb 16. PMID: 29453701; PMCID: PMC5978928.
Download PDF

1: Schmeel FC, Simon B, Luetkens JA, Träber F, Meyer C, Schmeel LC, Sabet A, Ezziddin S, Schild HH, Hadizadeh DR. 
Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization. 
J Cancer Res Clin Oncol. 2017 Aug;143(8):1531-1541. doi: 10.1007/s00432-017-2395-5. Epub 2017 Mar 19. PMID: 28317063.

2: Sabet A, Haug AR, Eiden C, Auernhammer CJ, Simon B, Bartenstein P, Biersack HJ, Ezziddin S. 
Efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. 
Am J Nucl Med Mol Imaging. 2017 Apr 15;7(2):74-83. PMID: 28533939; PMCID: PMC5435613.
Download PDF

3: Sabet A, Strauss AC, Schmolders J, Bornemann R, Sabet A, Oldenburg J, Pennekamp PH, Biersack HJ, Ezziddin S. 
Radiosynoviorthesis in hemophilic arthropathy: pathologic blood pool imaging on pre-therapeutic bone scintigraphy is not a predictor of treatment success. 
Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):461-467. doi: 10.1007/s00259-016-3549-4. Epub 2016 Oct 28. PMID: 27796541.

4: Schmeel FC, Simon B, Sabet A, Luetkens JA, Träber F, Schmeel LC, Ezziddin S, Schild HH, Hadizadeh DR. 
Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy. 
Eur Radiol. 2017 Mar;27(3):966-975. doi: 10.1007/s00330-016-4430-3. Epub 2016 Jun 7. PMID: 27271923.

5: Sabet A, Binse I, Dogan S, Koch A, Rosenbaum-Krumme SJ, Biersack HJ, Biermann K, Ezziddin S. 
Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma. 
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):190-195. doi: 10.1007/s00259-016-3485-3. Epub 2016 Aug 16. PMID: 27530124.

6: Müller SP, Ezziddin S, Antoch G, Lauenstein T, Amthauer H, Haug AR, Bockisch A. 
Selektive intraarterielle Radiotherapie (SIRT) maligner Lebertumoren [Selective intraarterial radiotherapy (SIRT) of malignant liver tumors]. 
Nuklearmedizin. 2017;56(5):162-170. German. doi: 10.3413/Nukmed-2017-05-0001. Epub 2018 Jan 4. PMID: 29533422.

7: Haqparwar J, Pepe A, Fassbender K, Dillmann U, Ezziddin S, Schaefer A, Leppert D, Spiegel J. 
Reduced MIBG accumulation of the parotid and submandibular glands in idiopathic Parkinson's disease. 
Parkinsonism Relat Disord. 2017 Jan;34:26-30. doi: 10.1016/j.parkreldis.2016.10.011. Epub 2016 Oct 15. PMID: 27769648.

1: Sabet A, Binse I, Grafe H, Ezziddin S, Görges R, Poeppel TD, Bockisch A, Rosenbaum-Krumme SJ. 
Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer. 
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1988-94. doi: 10.1007/s00259-016-3400-y. Epub 2016 Apr 27. PMID: 27118127.

2: Binse I, Poeppel TD, Ruhlmann M, Ezziddin S, Görges R, Sabet A, Beiderwellen K, Bockisch A, Rosenbaum-Krumme SJ. 
68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin. 
J Nucl Med. 2016 Oct;57(10):1512-1517. doi: 10.2967/jnumed.115.171942. Epub 2016 Mar 31. PMID: 27033897.
Download PDF

3: Fleckenstein J, Jelden M, Kremp S, Jagoda P, Stroeder J, Khreish F, Ezziddin S, Buecker A, Rübe C, Schneider GK. 
The Impact of Diffusion-Weighted MRI on the Definition of Gross Tumor Volume in Radiotherapy of Non-Small-Cell Lung Cancer. 
PLoS One. 2016 Sep 9;11(9):e0162816. doi: 10.1371/journal.pone.0162816. PMID: 27612171; PMCID: PMC5017760.
Download PDF

4: Bodei L, Modlin IM, Luster M, Forrer F, Cremonesi M, Hicks RJ, Ezziddin S, Kidd M, Chiti A. 
Myeloid neoplasms after chemotherapy and PRRT: myth and reality. 
Endocr Relat Cancer. 2016 Aug;23(8):C1-7. doi: 10.1530/ERC-16-0258. Epub 2016 Jun 28. PMID: 27353035. 
Download PDF

5: Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, Schreckenberger M, Krause BJ, Bengel FM, Bartenstein P, Biersack HJ, Pöpperl G, Baum RP. 
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. 
Eur J Cancer. 2016 May;58:41-51. doi: 10.1016/j.ejca.2016.01.009. Epub 2016 Mar 2. PMID: 26943056.

6: Donazzan L, Mahfoud F, Ewen S, Ukena C, Cremers B, Kirsch CM, Hellwig D, Eweiwi T, Ezziddin S, Esler M, Böhm M. 
Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. 
Clin Res Cardiol. 2016 Apr;105(4):364-71. doi: 10.1007/s00392-015-0930-4. Epub 2015 Oct 22. PMID: 26493305.

7: Sabet A, Biersack HJ, Ezziddin S. 
Advances in Peptide Receptor Radionuclide Therapy. 
Semin Nucl Med. 2016 Jan;46(1):40-6. doi: 10.1053/j.semnuclmed.2015.09.005. PMID: 26687856.

1: Fendler WP, Ilhan H, Paprottka PM, Jakobs TF, Heinemann V, Bartenstein P, Khalaf F, Ezziddin S, Hacker M, Haug AR. 
Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. 
Eur Radiol. 2015 Sep;25(9):2693-700. doi: 10.1007/s00330-015-3658-7. Epub 2015 Feb 28. PMID: 25721320.

2: Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, Mayer K, Biersack HJ, Ezziddin S. 
Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. 
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1238-46. doi: 10.1007/s00259-015-3041-6. Epub 2015 Mar 26. PMID: 25808630.

3: Ezziddin S, Bücker A, Lammert F. 
Radioembolization as a Treatment Option. 
Dtsch Arztebl Int. 2015 May 25;112(21-22):372-3. doi: 10.3238/arztebl.2015.0372b. PMID: 26149377; PMCID: PMC4496480.
Download PDF